Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration

Mamdouh M Kabeel1, Ashraf M El-Batarny2, Mohamed K Tameesh3, Moustafa A Abou El Enein11Tanta University, Egypt, currently affiliated to Magrabi Eye and Ear Hospital, KSA, Vitreoretinal Service; 2Tanta University, Egypt, currently affiliated to Magrabi Eye and Ear Hospital, Muscat, Oman, Vitreoretina...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mamdouh M Kabeel, Ashraf M El-Batarny, Mohamed K Tameesh, Moustafa A Abou El Enein
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d0b69aed370a4c7f9cb2bd15ca54c3dd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d0b69aed370a4c7f9cb2bd15ca54c3dd
record_format	dspace
spelling	oai:doaj.org-article:d0b69aed370a4c7f9cb2bd15ca54c3dd2021-12-02T07:11:47ZCombined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration1177-54671177-5483https://doaj.org/article/d0b69aed370a4c7f9cb2bd15ca54c3dd2008-03-01T00:00:00Zhttp://www.dovepress.com/combined-intravitreal-bevacizumab-and-photodynamic-therapy-with-vertip-a352https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Mamdouh M Kabeel1, Ashraf M El-Batarny2, Mohamed K Tameesh3, Moustafa A Abou El Enein11Tanta University, Egypt, currently affiliated to Magrabi Eye and Ear Hospital, KSA, Vitreoretinal Service; 2Tanta University, Egypt, currently affiliated to Magrabi Eye and Ear Hospital, Muscat, Oman, Vitreoretinal Service; 3Tanta University, Egypt, currently affiliated to Saad Specialist Hospital, KSA, Vitreoretinal ServicePurpose: To test the results for patients treated with combined photodynamic therapy (PDT) with vertiporfin (Visudyne, Novartis AG) and intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).Patients and methods: This is a prospective study including 18 eyes with subfoveal or juxtafoveal CNV secondary to AMD. Patients were treated with intravitreal bevacizumab 2.5 mg in the morning then PDT with vertiporfin in the evening of the same day. All patients were followed up for 6 months. The main outcome measures were stabilization (no change) or improvement of best corrected visual acuity (BCVA) with no leakage in fluorescein angiography (FLA) and reduction of central retinal thickness, and retreatment rate.Results: At the end of 6 months follow up, all cases had either stabilization or improved BCVA. Fifteen eyes (80%) showed improved BCVA. The overall mean improvement in BCVA (n = 18) was 2.17 lines. Fifteen eyes (80%) required single combined treatment. Only 3 eyes (20%) required retreatment with the same protocol. No systemic or ocular complications were reported.Conclusion: Combined intravitreal bevacizumab and PDT as a treatment of CNV secondary to AMD either for predominantly classic or occult subtypes has a positive therapeutic effect with stabilization or improvement of final BCVA and also might reduce the need for retreatment compared with literature retreatment rates of either modality alone.Summary: Eighteen patients receiving combined therapy with PDT and intravitreal bevacizumab for CNV secondary to AMD, showed not only significant visual improvement but also reduction in the frequency of retreatment when compared to the results of monotherapy with each modality.Keywords: intravitreal bevacizumab, photodynamic therapy, vertiporfin, choroidal neovascularization, age-related macular degeneration Mamdouh M KabeelAshraf M El-BatarnyMohamed K TameeshMoustafa A Abou El EneinDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 1, Pp 159-166 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Mamdouh M Kabeel Ashraf M El-Batarny Mohamed K Tameesh Moustafa A Abou El Enein Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
description	Mamdouh M Kabeel1, Ashraf M El-Batarny2, Mohamed K Tameesh3, Moustafa A Abou El Enein11Tanta University, Egypt, currently affiliated to Magrabi Eye and Ear Hospital, KSA, Vitreoretinal Service; 2Tanta University, Egypt, currently affiliated to Magrabi Eye and Ear Hospital, Muscat, Oman, Vitreoretinal Service; 3Tanta University, Egypt, currently affiliated to Saad Specialist Hospital, KSA, Vitreoretinal ServicePurpose: To test the results for patients treated with combined photodynamic therapy (PDT) with vertiporfin (Visudyne, Novartis AG) and intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).Patients and methods: This is a prospective study including 18 eyes with subfoveal or juxtafoveal CNV secondary to AMD. Patients were treated with intravitreal bevacizumab 2.5 mg in the morning then PDT with vertiporfin in the evening of the same day. All patients were followed up for 6 months. The main outcome measures were stabilization (no change) or improvement of best corrected visual acuity (BCVA) with no leakage in fluorescein angiography (FLA) and reduction of central retinal thickness, and retreatment rate.Results: At the end of 6 months follow up, all cases had either stabilization or improved BCVA. Fifteen eyes (80%) showed improved BCVA. The overall mean improvement in BCVA (n = 18) was 2.17 lines. Fifteen eyes (80%) required single combined treatment. Only 3 eyes (20%) required retreatment with the same protocol. No systemic or ocular complications were reported.Conclusion: Combined intravitreal bevacizumab and PDT as a treatment of CNV secondary to AMD either for predominantly classic or occult subtypes has a positive therapeutic effect with stabilization or improvement of final BCVA and also might reduce the need for retreatment compared with literature retreatment rates of either modality alone.Summary: Eighteen patients receiving combined therapy with PDT and intravitreal bevacizumab for CNV secondary to AMD, showed not only significant visual improvement but also reduction in the frequency of retreatment when compared to the results of monotherapy with each modality.Keywords: intravitreal bevacizumab, photodynamic therapy, vertiporfin, choroidal neovascularization, age-related macular degeneration
format	article
author	Mamdouh M Kabeel Ashraf M El-Batarny Mohamed K Tameesh Moustafa A Abou El Enein
author_facet	Mamdouh M Kabeel Ashraf M El-Batarny Mohamed K Tameesh Moustafa A Abou El Enein
author_sort	Mamdouh M Kabeel
title	Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
title_short	Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
title_full	Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
title_fullStr	Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
title_full_unstemmed	Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
title_sort	combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/d0b69aed370a4c7f9cb2bd15ca54c3dd
work_keys_str_mv	AT mamdouhmkabeel combinedintravitrealbevacizumabandphotodynamictherapywithvertiporfinformanagementofchoroidalneovascularizationsecondarytoagerelatedmaculardegeneration AT ashrafmelbatarny combinedintravitrealbevacizumabandphotodynamictherapywithvertiporfinformanagementofchoroidalneovascularizationsecondarytoagerelatedmaculardegeneration AT mohamedktameesh combinedintravitrealbevacizumabandphotodynamictherapywithvertiporfinformanagementofchoroidalneovascularizationsecondarytoagerelatedmaculardegeneration AT moustafaaabouelenein combinedintravitrealbevacizumabandphotodynamictherapywithvertiporfinformanagementofchoroidalneovascularizationsecondarytoagerelatedmaculardegeneration
_version_	1718399603776159744

Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration

Ejemplares similares